Lifecore Biomedical (LFCR) to Release Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) is expected to release its earnings data on Thursday, April 3rd. Analysts expect Lifecore Biomedical to post earnings of ($0.14) per share and revenue of $33.23 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Lifecore Biomedical (NASDAQ:LFCR) last issued its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Up 3.5 %

NASDAQ LFCR opened at $6.83 on Friday. The stock has a market cap of $252.88 million, a PE ratio of -12.20 and a beta of 0.96. The business has a 50 day moving average price of $6.14 and a two-hundred day moving average price of $6.17. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21. Lifecore Biomedical has a fifty-two week low of $3.68 and a fifty-two week high of $7.99.

Analysts Set New Price Targets

Separately, Stephens reiterated an “equal weight” rating and set a $6.00 target price on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

Insider Buying and Selling

In related news, CEO Paul Josephs bought 17,000 shares of the stock in a transaction on Wednesday, January 8th. The shares were purchased at an average price of $5.74 per share, with a total value of $97,580.00. Following the purchase, the chief executive officer now owns 559,717 shares in the company, valued at approximately $3,212,775.58. This represents a 3.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 32.20% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.